OXGR1 and obesity due to melanocortin 4 receptor deficiency: As an endogenous agonist of OXGR1, AKG has broad therapeutic potential such as extending lifespan [20], maintaining intestinal health [21], decreasing the risk of obesity [12], and facilitating macrophage activation via epigenetic alteration [22, 23].